$631 Million is the total value of Rhenman & Partners Asset Management AB's 104 reported holdings in Q1 2017. The portfolio turnover from Q4 2016 to Q1 2017 was 11.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| HZNP | Buy | Horizon Pharma Plc | $25,885,000 | +128.5% | 1,751,322 | +150.2% | 4.10% | +88.8% |
| ESPR | Buy | Esperion Therapeutics Inc | $19,186,000 | +457.2% | 543,347 | +97.6% | 3.04% | +360.3% |
| BIIB | Buy | Biogen Inc | $18,593,000 | +82.1% | 68,000 | +88.9% | 2.94% | +50.4% |
| GKOS | Buy | Glaukos Corp | $16,714,000 | +320.8% | 325,800 | +181.3% | 2.65% | +247.8% |
| AMGN | Buy | Amgen Inc | $16,407,000 | +72.6% | 100,000 | +53.8% | 2.60% | +42.6% |
| ABMD | Buy | Abiomed Inc | $14,654,000 | +26.6% | 117,048 | +14.0% | 2.32% | +4.6% |
| REGN | Buy | Regeneron Pharmaceuticals Inc | $14,338,000 | +47.4% | 37,000 | +39.6% | 2.27% | +21.8% |
| ALXN | Buy | Alexion Pharmaceuticals Inc | $13,543,000 | +20.7% | 111,702 | +21.8% | 2.14% | -0.3% |
| ITCI | Buy | Intra-Cellular Therapies Inc | $11,630,000 | +165.8% | 715,664 | +146.8% | 1.84% | +119.5% |
| ELGX | Buy | Endologix Inc | $11,584,000 | +252.2% | 1,600,000 | +178.3% | 1.83% | +190.6% |
| PFE | Buy | Pfizer Inc | $11,475,000 | +6.0% | 335,422 | +0.6% | 1.82% | -12.4% |
| NKTR | Buy | Nektar Therapeutics | $11,031,000 | +119.3% | 470,000 | +14.6% | 1.75% | +81.2% |
| BMRN | Buy | BioMarin Pharmaceutical Inc | $10,973,000 | +164.9% | 125,000 | +150.0% | 1.74% | +118.9% |
| NVRO | Buy | Nevro Corp | $10,552,000 | +62.6% | 112,614 | +26.1% | 1.67% | +34.3% |
| VRTX | Buy | Vertex Pharmaceuticals Inc | $10,390,000 | +116.9% | 95,013 | +46.1% | 1.64% | +79.2% |
| MRK | Buy | Merck & Co Inc | $10,166,000 | +146.7% | 160,000 | +128.6% | 1.61% | +103.8% |
| JAZZ | Buy | Jazz Pharmaceuticals Plc | $8,754,000 | +57.7% | 60,320 | +18.5% | 1.39% | +30.3% |
| KITE | Buy | Kite Pharma Inc | $8,634,000 | +140.7% | 110,000 | +37.5% | 1.37% | +98.7% |
| ABBV | Buy | AbbVie Inc | $8,471,000 | +17.6% | 130,000 | +13.0% | 1.34% | -2.8% |
| ALKS | Buy | Alkermes Plc | $8,214,000 | +95.5% | 140,409 | +85.7% | 1.30% | +61.4% |
| XNCR | Buy | Xencor Inc | $6,219,000 | +5.0% | 260,000 | +15.6% | 0.98% | -13.2% |
| CAH | Buy | Cardinal Health Inc | $6,116,000 | +30.7% | 75,000 | +15.4% | 0.97% | +8.0% |
| DVAX | Buy | Dynavax Technologies Corp | $5,859,000 | +205.8% | 984,696 | +103.0% | 0.93% | +152.9% |
| SAGE | New | Sage Therapeutics Inc | $5,164,000 | – | 72,659 | +100.0% | 0.82% | – |
| ABT | New | Abbott Laboratories | $5,107,000 | – | 115,000 | +100.0% | 0.81% | – |
| ENDP | Buy | Endo International Plc | $4,490,000 | -9.2% | 402,303 | +34.0% | 0.71% | -25.0% |
| UHS | Buy | Universal Health Services Inc B | $4,356,000 | +36.5% | 35,000 | +16.7% | 0.69% | +12.7% |
| AERI | Buy | Aerie Pharmaceuticals Inc | $3,855,000 | +190.9% | 85,000 | +142.9% | 0.61% | +140.2% |
| FGEN | Buy | FibroGen Inc | $3,805,000 | +70.9% | 154,341 | +48.4% | 0.60% | +41.2% |
| WBA | Buy | Walgreens Boots Alliance Inc | $3,737,000 | +80.6% | 45,000 | +80.0% | 0.59% | +49.1% |
| DVA | Buy | DaVita Inc | $3,738,000 | +29.4% | 55,000 | +22.2% | 0.59% | +6.9% |
| NBIX | Buy | Neurocrine Biosciences Inc | $3,681,000 | +137.8% | 85,000 | +112.5% | 0.58% | +96.3% |
| MYL | Buy | Mylan N.V. | $3,509,000 | +818.6% | 90,000 | +800.0% | 0.56% | +661.6% |
| ICPT | Buy | Intercept Pharmaceuticals Inc | $3,393,000 | +56.1% | 30,000 | +50.0% | 0.54% | +28.8% |
| MGNX | Buy | Macrogenics Inc | $3,255,000 | +2.7% | 175,000 | +12.9% | 0.52% | -15.2% |
| IMMU | New | Immunomedics Inc | $3,103,000 | – | 479,610 | +100.0% | 0.49% | – |
| ACAD | Buy | Acadia Pharmaceuticals Inc | $3,094,000 | +53.2% | 90,000 | +28.6% | 0.49% | +26.6% |
| ISRG | New | Intuitive Surgical Inc | $3,066,000 | – | 4,000 | +100.0% | 0.49% | – |
| RDUS | Buy | Radius Health Inc | $2,899,000 | +38.6% | 75,000 | +36.4% | 0.46% | +14.5% |
| ADMS | Buy | Adamas Pharmaceuticals Inc | $2,713,000 | +23.5% | 155,000 | +19.2% | 0.43% | +2.1% |
| BIVV | New | Bioverativ Inc Reg S | $1,688,000 | – | 31,000 | +100.0% | 0.27% | – |
| RGLS | Buy | Regulus Therapeutic Inc | $979,000 | -7.0% | 593,629 | +26.8% | 0.16% | -23.3% |
| CATB | Buy | Catabasis Pharmaceuticals Inc | $497,000 | +37.7% | 310,756 | +210.8% | 0.08% | +14.5% |
| JPM | Buy | JPMorgan Chase & Co | $425,000 | +20.4% | 4,837 | +18.4% | 0.07% | -1.5% |
| WFC | Buy | Wells Fargo & Co | $407,000 | +20.8% | 7,305 | +19.4% | 0.06% | -1.5% |
| XOM | Buy | Exxon Mobil Corp | $396,000 | +37.5% | 4,823 | +51.0% | 0.06% | +14.5% |
| HAL | Buy | Halliburton Co (Hg Co) | $380,000 | +42.3% | 7,718 | +56.5% | 0.06% | +17.6% |
| QCOM | Buy | Qualcomm Inc | $308,000 | +14.5% | 5,368 | +30.1% | 0.05% | -5.8% |
| BUD | Buy | Anheuser-Busch InBev SA ADR spons repr 1 Share | $308,000 | +33.9% | 2,806 | +28.7% | 0.05% | +11.4% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-04-19
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| UNITEDHEALTH GROUP INC | 40 | Q3 2023 | 4.0% |
| BIOMARIN PHARMACEUTICAL INC | 40 | Q3 2023 | 5.0% |
| ALKERMES PLC | 40 | Q3 2023 | 3.3% |
| LILLY ELI & CO | 39 | Q3 2023 | 5.8% |
| CVS HEALTH CORP | 39 | Q3 2023 | 3.5% |
| INTRA-CELLULAR THERAPIES INC | 39 | Q3 2023 | 2.4% |
| EDWARDS LIFESCIENCES CORP | 39 | Q3 2023 | 1.7% |
| VERTEX PHARMACEUTICALS INC | 38 | Q3 2023 | 4.3% |
| REVANCE THERAPEUTICS INC | 38 | Q3 2023 | 0.9% |
| ABBVIE INC | 37 | Q3 2023 | 4.4% |
View Rhenman & Partners Asset Management AB's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-14 |
| 13F-HR | 2024-02-13 |
| 13F-HR/A | 2023-11-13 |
| 13F-HR | 2023-11-09 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-12 |
| 13F-HR | 2022-05-13 |
View Rhenman & Partners Asset Management AB's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.